Kura Oncology Reports Strong Clinical Activity and Safety with Darlifarnib + Adagrasib in KRAS G12C-Mutated Solid Tumors
Kura Oncology announced encouraging first-in-human data from its FIT-001 trial evaluating darlifarnib plus adagrasib in heavily pretreated patients with KRAS G12C-mutated advanced solid tumors, including pancreatic, lung, and colorectal cancers. Tumor shrinkage was observed in 77% of evaluable patients with objective response rates of 67% in pancre…